Loading viewer...
earnings
Format: PDF earnings
Intercept Pharmaceuticals' third-quarter 2016 earnings presentation covering the commercialization of Ocaliva® for primary biliary cholangitis (PBC) in the U.S. and regulatory progress internationally, along with financial and operational updates. The presentation outlines the company's U.S. launch strategy, international expansion plans, and adjusted operating expense guidance.
earnings
21 Pages
Lam Research Corporation
Krishna Institute of Medical Sciences Q1 FY2022 Earnings Update
earningsearnings
28 Pages
Krishna Institute of Medical Sciences Limited